News headlines about Ascendis Pharma A/S (NASDAQ:ASND) have been trending somewhat positive this week, according to Accern. The research group identifies negative and positive media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Ascendis Pharma A/S earned a coverage optimism score of 0.19 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 45.570952095773 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Here are some of the headlines that may have impacted Accern’s rankings:
- Ascendis Pharma A/S (ASND) Given Consensus Rating of “Buy” by Analysts (americanbankingnews.com)
- 73,771 Shares in Ascendis Pharma A/S (ASND) Purchased by University of Notre Dame DU Lac (americanbankingnews.com)
- Ascendis Pharma A/S (ASND) Holdings Trimmed by VHCP Management II LLC (americanbankingnews.com)
- Emory University Trims Holdings in Ascendis Pharma A/S (ASND) (americanbankingnews.com)
ASND has been the subject of several recent analyst reports. JPMorgan Chase & Co. set a $50.00 target price on shares of Ascendis Pharma A/S and gave the company a “buy” rating in a research note on Wednesday, January 3rd. BidaskClub raised shares of Ascendis Pharma A/S from a “hold” rating to a “buy” rating in a research note on Wednesday, December 27th. HC Wainwright reaffirmed a “buy” rating on shares of Ascendis Pharma A/S in a research note on Wednesday, December 13th. Bank of America lowered their target price on shares of Ascendis Pharma A/S from $46.00 to $43.00 and set a “buy” rating for the company in a research note on Friday, November 17th. Finally, Credit Suisse Group reaffirmed a “buy” rating and issued a $50.00 target price on shares of Ascendis Pharma A/S in a research note on Sunday, February 25th. Three analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $52.67.
Ascendis Pharma A/S Company Profile
Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop sustained release prodrug therapies with several product candidates in clinical and preclinical development. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications.
Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.